25, 1949; and defendant Turnbow caused a quantity of *thyroid tablets* to be repacked and sold without a prescription on or about September 26, 1949. It was alleged also that such acts of the defendants resulted in the repackaged drugs being misbranded.

NATURE OF CHARGE: Misbranding, Section 502 (b) (2), the repackaged drugs failed to bear labels containing statements of the quantity of the contents; Section 502 (f) (1), the labeling of the repackaged drugs bore no directions for use; and, Section 502 (f) (2), the labeling of the repackaged *sulfadiazine tablets* bore no warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration.

DISPOSITION: October 23, 1950. Pleas of nolo contendere having been entered on behalf of the defendants, the court imposed fines of $100 against defendant Wilson, $100 against defendant Kolb, and $50 against defendant Turnbow.

3283. Misbranding of Seconal Sodium capsules and Benzedrine Sulfate tablets. U. S. v. Stephen E. Piotrowski (Stephen E. Piotrowski Pharmacy). Plea of guilty. Fine, $300. (F. D. C. No. 29454. Sample Nos. 60660–K to 60664–K, incl.)

INFORMATION FILED: September 11, 1950, Eastern District of Wisconsin, against Stephen E. Piotrowski, trading as the Stephen E. Piotrowski Pharmacy, Milwaukee, Wis.

INTERSTATE SHIPMENT: From the States of Indiana and Pennsylvania, into the State of Wisconsin, of quantities of *Seconal Sodium capsules* and *Benzedrine Sulfate tablets.*

ALLEGED VIOLATION: On or about September 28 and 30 and October 1, 13, and 18, 1949, while the drugs were being held for sale after shipment in interstate commerce, the defendant caused a number of the capsules and tablets to be repacked and sold without a prescription, which acts of the defendant resulted in the repackaged drugs being misbranded.

NATURE OF CHARGE: Misbranding, Sections 502 (b) (1) and (2), the repackaged drugs failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor, and a statement of the quantity of the contents; and, Section 502 (f) (1), the labeling of the repackaged drugs bore no directions for use.

Further misbranding, Section 502 (d), the *Seconal Sodium capsules* contained a chemical derivative of barbituric acid, which derivative, the Federal Security Administrator, after investigation, has found to be, and by regulations designated as, habit forming; and the label of the repackaged capsules failed to bear the name, and quantity or proportion of such derivative and in juxtaposition therewith the statement "Warning—May be habit forming."

Further misbranding, Section 502 (e) (1), a portion of the repackaged *Benzedrine Sulfate tablets* failed to bear a label containing the common or usual name of the drug.

DISPOSITION: November 27, 1950. A plea of guilty having been entered, the court imposed a fine of $300.

3284. Misbranding of Seconal Sodium capsules. U. S. v. Edwin E. Wiegand. Plea of nolo contendere. Fine of $1,000 on count 1; sentence suspended on remaining three counts of information and defendant placed on probation for 1 year. (F. D. C. No. 29450. Sample Nos. 41977–K, 41978–K, 59949–K, 59957–K.)